Cases & Deals

Astellas acquires Iveric bio

Clients Astellas Pharma Inc.

Jones Day is advising Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.

Upon completion of the transaction, Iveric will no longer be traded or listed on any public securities exchange. The transaction is expected to close in the third quarter of 2023, subject to customary closing conditions.